Skip to main content

09-09-2022 | COVID-19 | News

News in brief

Microvascular complications linked to COVID-19 mortality risk in people with type 2 diabetes

Author: Alba Ruzafa


medwireNews: Study findings published in Diabetes, Obesity and Metabolism suggest that the presence of microvascular complications is associated with increased risk for all-cause mortality in people with type 2 diabetes hospitalized for COVID-19.

This suggests these complications play a “deleterious” role in this population and supports a “systematic search for microvascular complications for any patient with diabetes and COVID-19 to identify patients at high mortality risk,” say Samy Hadjadj (Nantes Université, France) and co-authors.

The study analyzed data for 2951 participants from the French CORONADO study, 3387 from the UK ABCD COVID-19 audit, and 9327 from the US AMERICADO study. Microvascular diabetic complications, including retinopathy, kidney disease, and/or history of foot ulcer, were reported in 44.5%, 53.4%, and 79.0% of each group, respectively.

These individuals with any microvascular complication had a corresponding 3.86-, 1.67-, and 1.58-fold higher risk for all-cause mortality versus those without. In particular, the researchers note that the presence of diabetic kidney disease alone was associated with all-cause mortality risk “[i]n a very consistent manner in all 3 study populations,” with significant odds ratios of 2.53, 1.24, and 1.66, respectively.

A meta-analysis of the three studies showed that participants with microvascular complications had a significant 1.50-fold elevated risk for all-cause mortality after adjustment for age, sex, hypertension, and cardiovascular disease.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Obes Metab 2022; doi:10.1111/dom.14845

9 September 2022: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video